MARKET

NMRA

NMRA

Neumora Therapeutics Inc
NASDAQ
3.260
+0.260
+8.67%
Opening 14:21 02/12 EST
OPEN
2.950
PREV CLOSE
3.000
HIGH
3.465
LOW
2.890
VOLUME
3.62M
TURNOVER
--
52 WEEK HIGH
3.465
52 WEEK LOW
0.6110
MARKET CAP
554.03M
P/E (TTM)
-2.2281
1D
5D
1M
3M
1Y
5Y
1D
Differentiated NMRA-511 Efficacy and Safety in Alzheimer’s Agitation Support Buy Rating on Neumora
TipRanks · 1d ago
Strengthening NMRA-511 Clinical Profile and Upside Potential Underpin Buy Rating and $18 Target
TipRanks · 1d ago
Neumora Therapeutics unveils new pipeline targeting neuropsychiatric and metabolic diseases
Reuters · 1d ago
Does Neumora Therapeutics’ (NMRA) Guggenheim Spotlight Recast Its Core Neuroscience Investment Narrative?
Simply Wall St · 1d ago
3 Promising Penny Stocks With Market Caps Up To $400M
Simply Wall St · 3d ago
Weekly Report: what happened at NMRA last week (0202-0206)?
Weekly Report · 3d ago
Neumora Therapeutics to Join Guggenheim Emerging Outlook Biotech Summit
Reuters · 02/04 12:00
Weekly Report: what happened at NMRA last week (0126-0130)?
Weekly Report · 02/02 09:25
More
About NMRA
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The Company's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).

Webull offers Neumora Therapeutics Inc stock information, including NASDAQ: NMRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NMRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NMRA stock methods without spending real money on the virtual paper trading platform.